Debongnie J C
Service de gastroentérologie, Clinique St-Pierre, Ottignies.
Acta Gastroenterol Belg. 1992 Sep-Dec;55(5-6):415-22.
Inhibition of H2 receptors has been the first fully evaluated treatment of peptic ulcer and remains the most widely used mode of therapy. In this review, we summarize the current data on clinical pharmacology, therapeutic indications and results of the four currently used drugs: cimetidine - ranitidine - pepticidine - nizatidine. Their similarities are stressed. Recent data are underlined. The superiority or necessity of a single evening dose is questioned, as well as the clinical importance of tolerance and rebound. The effect on gastric alcohol dehydrogenase is mentioned pending further work on the clinical importance of this discovery. In the acute treatment, the antisecretory potency is of major importance in duodenal ulcer, the duration of treatment in gastric ulcer. Maintenance treatment prevents complication as well as recurrence. H2 receptor antagonists remain a primary treatment of peptic ulcer.
H2受体拮抗剂的应用是对消化性溃疡的首个全面评估的治疗方法,并且仍是应用最为广泛的治疗方式。在本综述中,我们总结了目前关于四种现用药物(西咪替丁、雷尼替丁、法莫替丁、尼扎替丁)临床药理学、治疗适应证及治疗结果的现有数据。强调了它们的相似之处,突出了最新数据。质疑了单日晚剂量给药的优越性或必要性,以及耐受性和反跳的临床重要性。在进一步研究这一发现的临床重要性之前,提及了对胃酒精脱氢酶的影响。在急性治疗中,抗分泌效力对十二指肠溃疡至关重要,而治疗时长对胃溃疡至关重要。维持治疗可预防并发症及复发。H2受体拮抗剂仍是消化性溃疡的主要治疗药物。